Effects of Rapamycin in the Eker Rat Model of Tuberous Sclerosis Complex

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Pediatric Research

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1203/01.PDR.0000147727.78571.07PMID 15557109
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• mTOR Controls Cell Cycle Progression through Its Cell Growth Effectors S6K1 and 4E-BP1/Eukaryotic Translation Initiation Factor 4E

  2004cited by this paper
• TSC2 regulates VEGF through mTOR-dependent and -independent pathways.

  2003cited by this paper
• Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb.

  2003cited by this paper
• The tuberin-hamartin complex negatively regulates beta-catenin signaling activity.

  2003cited by this paper
• Rheb is an essential regulator of S6K in controlling cell growth in Drosophila

  2003cited by this paper
• Rapamycins: Mechanisms of Action and Cellular Resistance

  2003cited by this paper
• The Tuberin-Hamartin Complex Negatively Regulates β-Catenin Signaling Activity*

  2003cited by this paper
• Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins

  2003cited by this paper
• TOR Signaling

  2003cited by this paper
• TSC2 mediates cellular energy response to control cell growth and survival.

  2003cited by this paper
• Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors.

  2002influential reference
• Tuberous sclerosis complex and neurofibromatosis type 1: the two most common neurocutaneous diseases.

  2002cited by this paper
• TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling

  2002cited by this paper
• Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway.

  2002cited by this paper
• TSC1–TSC2: a complex tale of PKB-mediated S6K regulation

  2002cited by this paper
• Tuberin Regulates p70 S6 Kinase Activation and Ribosomal Protein S6 Phosphorylation

  2002cited by this paper
• Genetic identification of a locus, Mot1, that affects renal tumor size in the rat.

  2001cited by this paper
• Two genetic hits (more or less) to cancer

  2001cited by this paper
• Definition and Criteria for Diagnosis

  1999cited by this paper
• Tsc2(+/-) mice develop tumors in multiple sites that express gelsolin and are influenced by genetic background.

  1999cited by this paper
• Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34.

  1997cited by this paper
• Subependymal astrocytic hamartomas in the Eker rat model of tuberous sclerosis.

  1997influential reference
• Allelic loss is frequent in tuberous sclerosis kidney lesions but rare in brain lesions.

  1996cited by this paper
• Predisposition to renal carcinoma in the Eker rat is determined by germ-line mutation of the tuberous sclerosis 2 (TSC2) gene.

  1994cited by this paper
• The tuberous sclerosis gene on chromosome 9q34 acts as a growth suppressor.

  1994cited by this paper
• Spontaneous and radiation-induced renal tumors in the Eker rat model of dominantly inherited cancer.

  1993cited by this paper
• Predisposition to renal cell carcinoma due to alteration of a cancer susceptibility gene.

  1992cited by this paper
• Hereditary renal adenomas and adenocarcinomas in rats.

  1981cited by this paper

• Tuberous Sclerosis Complex and the kidneys: what nephrologists need to know

  2024cites this paper
• Complexo da Esclerose Tuberosa e rins: o que os nefrologistas devem saber

  2024cites this paper
• Tyrosine Kinase Inhibitors Diminish Renal Neoplasms in a Tuberous Sclerosis Model Via Induction of Apoptosis

  2023cites this paper
• The Evolving Landscape of Therapeutics for Epilepsy in Tuberous Sclerosis Complex

  2023cites this paper
• Developmental effects of constitutive mTORC1 hyperactivity and environmental enrichment on structural synaptic plasticity and behaviour in a rat model of autism spectrum disorder

  2022cites this paper
• Defining the Magnetic Resonance Features of Renal Lesions and Their Response to Everolimus in a Transgenic Mouse Model of Tuberous Sclerosis Complex

  2022influential citation
• Prospective nanoparticle treatments for lymphangioleiomyomatosis

  2022cites this paper
• The paradox of autophagy in Tuberous Sclerosis Complex

  2021cites this paper
• Phakomatoses and Endocrine Gland Tumors: Noteworthy and (Not so) Rare Associations

  2021cites this paper
• An insight of scientific developments in TSC for better therapeutic strategy.

  2020cites this paper
• Choosing The Right Animal Model for Renal Cancer Research☆

  2020cites this paper
• Energy sensors and reproductive hypothalamo-pituitary ovarian axis (HPO) in female mammals: role of mTOR (mammalian target of rapamycin), AMPK (AMP-activated protein kinase) and SIRT1 (Sirtuin 1).

  2020cites this paper
• PTEN inhibitor VO-OHpic suppresses TSC2-/- MEFs proliferation by excessively inhibiting autophagy via the PTEN/PRAS40 pathway

  2020cites this paper
• An update on the central nervous system manifestations of tuberous sclerosis complex

  2019cites this paper
• mTOR inhibitor reverses autistic-like social deficit behaviours in adult rats with both Tsc2 haploinsufficiency and developmental status epilepticus

  2017cites this paper
• Treatment of Lymphangioleiomyomatosis (LAM)

  2017cites this paper
• Exploiting Fission Yeast Genetic Interaction Data to Identify Disease-Specific Drug Targets for Tuberous Sclerosis Complex

  2017cites this paper
• Mourning Dr. Alfred G. Knudson: the two‐hit hypothesis, tumor suppressor genes, and the tuberous sclerosis complex

  2017cites this paper
• mTOR promotes pituitary tumor development through activation of PTTG1

  2017cites this paper
• A brain proteomic investigation of rapamycin effects in the Tsc1+/− mouse model

  2017cites this paper
• Estrogen maintains myometrial tumors in a lymphangioleiomyomatosis model.

  2016cites this paper
• New Indications of mTOR Inhibitors in Rare Tumors

  2016cites this paper
• Lymphangioleiomyomatosis: Current understanding and potential treatments.

  2016cites this paper
• Role of mTOR Inhibitors in Growth Hormone-Producing Pituitary Adenomas Harboring Different FGFR4 Genotypes.

  2016cites this paper
• Management of side effects of mTOR inhibitors in tuberous sclerosis patients

  2016cites this paper
• Cutaneous perivascular epithelioid cell tumors: A review on an infrequent neoplasm.

  2016cites this paper
• Perivascular epithelioid cell tumor of the ileum. A case report.

  2016cites this paper
• mTOR Hyperactivation by Ablation of Tuberous Sclerosis Complex 2 in the Mouse Heart Induces Cardiac Dysfunction with the Increased Number of Small Mitochondria Mediated through the Down-Regulation of Autophagy

  2016cites this paper
• Lymphangioleiomyomatosis (LAM): Molecular Insights into mTOR Regulation Lead to Targeted Therapies

  2016cites this paper
• Systemic effects of treatment with mTOR inhibitors in tuberous sclerosis complex: a comprehensive review

  2016cites this paper
• Exosomes mediate the acquisition of the disease phenotypes by cells with normal genome in tuberous sclerosis complex

  2016cites this paper
• Mammalian Target of Rapamycin Inhibitors and Life-Threatening Conditions in Tuberous Sclerosis Complex.

  2015cites this paper
• PHAKOMATOSIS: INTRESTING CASES OF TUBEROUS SCLEROSIS WITH RETINAL ASTROCYTOMA

  2015cites this paper
• Clinicopathological Correlates of Pituitary Adenoma

  2015cites this paper
• The Dissection of Signaling Cascades in Neural Stem Cell Proliferation & GBM Promotion

  2014cites this paper
• Herbal Therapeutics that Block the Oncogenic Kinase PAK1: A Practical Approach towards PAK1‐dependent Diseases and Longevity

  2014cites this paper
• Management of lymphangioleiomyomatosis

  2014cites this paper
• PROGRESS and FUTURE DIRECTIONS

  2014cites this paper
• A Vascular Model of Tsc1 Deficiency Accelerates Renal Tumor Formation with Accompanying Hemangiosarcomas

  2014cites this paper
• The PI3K/AKT/mTOR pathway in the pathophysiology and treatment of pituitary adenomas.

  2014cites this paper
• Targeting the mTOR signalling pathway for prevention and therapy of tuberous sclerosis in mouse models

  2013influential citation
• PAK1 in Brain Diseases or Disorders

  2013cites this paper
• Uterine-Specific Knockout of Tsc-2: A Mouse Model for Lymphangioleiomyomatosis

  2013cites this paper
• Uterine-specific loss of Tsc2 leads to myometrial tumors in both the uterus and lungs.

  2013cites this paper
• Apoptose precoce, proliferação celular sincrônica tardia e perfil de expressão de proteínas ao complexo esclerose tuberosa e às doenças renais policísticas durante tubulogênese in vitro

  2013cites this paper
• The role of TSC2 and deptor in fetal cortical development

  2012cites this paper
• Optimizing treatments for lymphangioleiomyomatosis

  2012cites this paper
• Therapeutic Trial of Metformin and Bortezomib in a Mouse Model of Tuberous Sclerosis Complex (TSC)

  2012cites this paper
• Finding a better drug for epilepsy: The mTOR pathway as an antiepileptogenic target

  2012cites this paper
• Reduced effect of stimulation of AMPA receptors on cerebral O₂ consumption in a rat model of autism.

  2012influential citation
• Lymphangioleiomyomatosis: New Concepts in Pathogenesis, Diagnosis, and Treatment

  2012cites this paper
• Advances in the management of subependymal giant cell astrocytoma

  2012cites this paper
• Lymphangioleiomyomatosis - a wolf in sheep's clothing.

  2012cites this paper
• Cystic diseases of the kidneys

  2012cites this paper
• Progress in the treatment of lymphangioleiomyomatosis: from bench to bedside.

  2012cites this paper
• 2 Tuberous Sclerosis Complex

  2012cites this paper
• Renal Dysgenesis and Cystic Disease of the Kidney

  2012cites this paper
• CHARACTERIZATION AND TREATMENT OF A NOVEL MOUSE MODEL OF TSC-ASSOCIATED AUTISM

  2012cites this paper
• Tuberous sclerosis complex: genetic basis and management strategies

  2012cites this paper
• Targeting the dysregulated mammalian target of rapamycin pathway in organ transplantation: killing 2 birds with 1 stone.

  2011cites this paper
• Effective neurofibromatosis therapeutics blocking the oncogenic kinase PAK1.

  2011cites this paper
• Pml represses tumour progression through inhibition of mTOR

  2011cites this paper
• Non-canonical functions of the tuberous sclerosis complex-Rheb signalling axis

  2011cites this paper
• Loss of the tuberous sclerosis complex protein tuberin causes Purkinje cell degeneration.

  2011cites this paper
• Changes in lung function and chylous effusions in patients with lymphangioleiomyomatosis treated with sirolimus.

  2011cites this paper
• Tuberous sclerosis complex

  2011cites this paper
• Novel Aspects on Epilepsy

  2011cites this paper
• Avaliação dos efeitos da doxiciclina sobre o bloqueio de metaloproteinases e na evolução funcional das pacientes com linfangioleiomiomatose

  2011cites this paper
• mTOR inhibition as a therapeutic strategy in tuberous sclerosis or sporadic lymphangioleiomyomatosis

  2011cites this paper
• Glucose deprivation in tuberous sclerosis complex-related tumors

  2011cites this paper
• The long and winding road to rational treatment of cancer associated with LKB1/AMPK/TSC/mTORC1 signaling

  2011cites this paper
• Oral and neurocutaneous phenotypes of familial tuberous sclerosis.

  2011cites this paper
• Identification of TGFβ signaling, p53, and actin stress fibers as targets of LKB1 tumor suppressor activity

  2011cites this paper
• Deficiency of the Erc/mesothelin gene ameliorates renal carcinogenesis in Tsc2 knockout mice

  2011cites this paper
• Sirolimus Therapy for Angiomyolipoma in Tuberous Sclerosis and Sporadic Lymphangioleiomyomatosis: A Phase 2 Trial

  2011cites this paper
• Everolimus tablets for patients with subependymal giant cell astrocytoma

  2011cites this paper
• mTORC2 Is Required for Proliferation and Survival of TSC2-Null Cells

  2011cites this paper
• The Role of the TSC 1 / 2 Complex in Tumor Development Professor of Surgery

  2011cites this paper
• Cystogenic potential of CD133+ progenitor cells of human polycystic kidneys

  2011cites this paper
• Tuberous sclerosis complex: tumors and tumorigenesis

  2011cites this paper
• Milestones in lymphangioleiomyomatosis research

  2011cites this paper
• Emerging Pharmacotherapies for Neurodevelopmental Disorders

  2010cites this paper
• The History of Tuberous Sclerosis Complex

  2010cites this paper
• Endocrine, gastrointestinal, hepatic, and lymphatic manifestations of tuberous sclerosis complex

  2010cites this paper
• Guidelines for the welfare and use of animals in cancer research

  2010cites this paper
• Sirolimus in renal transplant recipients with tuberous sclerosis complex: clinical effectiveness and implications for innate immunity

  2010cites this paper
• Rapamycin (sirolimus) in tuberous sclerosis associated pediatric central nervous system tumors

  2010cites this paper
• Clinical Trials for Rare Lung Diseases: Lessons from Lymphangioleiomyomatosis

  2010cites this paper
• Rapamycin ameliorates PKD resulting from conditional inactivation of Pkd1.

  2010cites this paper
• The link between the centrosome, TSC disease and epithelial differentiation

  2010cites this paper
• Comparison of three rapamycin dosing schedules in A/J Tsc2+/- mice and improved survival with angiogenesis inhibitor or asparaginase treatment in mice with subcutaneous tuberous sclerosis related tumors

  2010cites this paper
• Age dependence of radiation‐induced renal cell carcinomas in an Eker rat model

  2010cites this paper
• Rat and Mouse Models of Tuberous Sclerosis

  2010cites this paper
• Targeted treatments for cognitive and neurodevelopmental disorders in tuberous sclerosis complex

  2010cites this paper
• Rapamycin as an alternative to surgical treatment of subependymal giant cell astrocytomas in a patient with tuberous sclerosis complex.

  2010cites this paper
• Tuberous Sclerosis Complex and the Mammalian Target of Rapamycin Pathways

  2010cites this paper
• Dysregulation of TOR Signaling in Tuberous Sclerosis and Lymphangioleiomyomotosis

  2010cites this paper
• Exceptional Cases Low-dose rapamycin reduces kidney volume angiomyolipomas and prevents the loss of renal function in a patient with tuberous sclerosis complex

  2010cites this paper
• Targeted treatments for cognitive and neurodevelopmental disorders in tuberous sclerosis complex.

  2010cites this paper
• Animal Models of Lymphangioleiomyomatosis (LAM) and Tuberous Sclerosis Complex (TSC)

  2010influential citation